


Cefpiramide sodium

Cat. No.:	HY-B0798
CAS No.:	74849-93-7
Molecular Formula:	C ₂₅ H ₂₃ N ₈ NaO ₇ S ₂
Molecular Weight:	634.62
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture and light * The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 39 mg/mL (61.45 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.5757 mL	7.8787 mL	15.7575 mL
	5 mM	0.3151 mL	1.5757 mL	3.1515 mL
	10 mM	0.1576 mL	0.7879 mL	1.5757 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.28 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Cefpiramide sodium (SM-1652; Wy-44635) is a new Pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity. IC₅₀ value: Target: antibacterial agent Cefpiramide was moderately susceptible to hydrolysis by a variety of beta-lactamases from Gram-negative bacilli. cefpiramide was more active against Acinetobacter spp. and Pseudomonas spp. Like most other cephalosporins, cefpiramide inhibited methicillin-susceptible staphylococci, non-enterococcal streptococci, Neisseria gonorrhoeae, N. meningitidis and beta-lactamase-negative Haemophilus influenzae [1]. Pharmacokinetic studies in mice showed that cefpiramide attained a peak serum concentration of 12 micrograms/ml and a serum half-life of 40 min, which are higher than attained by cefoperazone with values of 4 micrograms/ml and 18 min. These factors may have caused the combined cefpiramide-gentamicin therapy to result in significantly improved survival

rates in mice as well as in higher bactericidal titers than the cefoperazone-gentamicin combination [2]. Cefpiramide inhibited many *Pseudomonas aeruginosa* resistant to carbenicillin, piperacillin, and cefotaxime, but it was less active than ceftazidime and cefsulodin. Cefpiramide inhibited staphylococci and streptococci and had appreciable activity against *Streptococcus faecalis* and *Listeria monocytogenes* [3].

IC₅₀ & Target

β-lactam

REFERENCES

[1]. Barry AL, et al. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. *J Antimicrob Chemother.* 1985 Sep;16(3):315-25.

[2]. Fu KP, et al. Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice. *Chemotherapy.* 1986;32(2):166-72.

[3]. Neu HC, et al. The in vitro activity and beta-lactamase stability of cefpiramide compared with other beta-lactam antibiotics. *Diagn Microbiol Infect Dis.* 1985 Nov;3(6):479-88.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA